In addition, although atRA and synthetic RAR agonists were reported to alleviate NAFLD in preclinical studies, little research has focused on the therapeutic potential of increasing RARα expression and regulating RARα-mediated transcriptional cascade for the treatment of NASH. The gene discussed is RARA; the disease is metabolic dysfunction-associated steatohepatitis.